

# KOS Diagnostic Lab (A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mr. JARMAN SINGH

AGE/ GENDER : 74 YRS/MALE PATIENT ID : 1645690

COLLECTED BY : REG. NO./LAB NO. : 012410170023

 REFERRED BY
 : 17/Oct/2024 10:26 AM

 BARCODE NO.
 : 01519042
 COLLECTION DATE
 : 17/Oct/2024 10:27 AM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 17/Oct/2024 11:47 AM

**CLIENT ADDRESS**: 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

## HAEMATOLOGY COMPLETE BLOOD COUNT (CBC)

#### **RED BLOOD CELLS (RBCS) COUNT AND INDICES**

HAEMOGLOBIN (HB) by CALORIMETRIC	12.8	gm/dL	12.0 - 17.0
RED BLOOD CELL (RBC) COUNT by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	4.35	Millions/cmm	3.50 - 5.00
PACKED CELL VOLUME (PCV) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	40.2	%	40.0 - 54.0
MEAN CORPUSCULAR VOLUME (MCV) by Calculated by automated hematology analyzer	92.3	fL	80.0 - 100.0
MEAN CORPUSCULAR HAEMOGLOBIN (MCH) by Calculated by automated hematology analyzer	29.5	pg	27.0 - 34.0
MEAN CORPUSCULAR HEMOGLOBIN CONC. (MCHC) by calculated by automated hematology analyzer	31.8 <sup>L</sup>	g/dL	32.0 - 36.0
RED CELL DISTRIBUTION WIDTH (RDW-CV) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	12.6	%	11.00 - 16.00
RED CELL DISTRIBUTION WIDTH (RDW-SD) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	44.9	fL	35.0 - 56.0
MENTZERS INDEX by CALCULATED	21.22	RATIO	BETA THALASSEMIA TRAIT: < 13.0 IRON DEFICIENCY ANEMIA: >13.0
GREEN & KING INDEX by CALCULATED	26.8	RATIO	BETA THALASSEMIA TRAIT:<= 65.0 IRON DEFICIENCY ANEMIA: > 65.0
WHITE BLOOD CELLS (WBCS)			
TOTAL LEUCOCYTE COUNT (TLC) by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	6510	/cmm	4000 - 11000
NUCLEATED RED BLOOD CELLS (nRBCS) by automated 6 part hematology analyzer	NIL		0.00 - 20.00
NUCLEATED RED BLOOD CELLS (nRBCS) % by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER  DIFFERENTIAL LEUCOCYTE COUNT (DLC)	NIL	%	< 10 %
NEUTROPHILS by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	58	%	50 - 70



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)





(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mr. JARMAN SINGH

**AGE/ GENDER** : 74 YRS/MALE **PATIENT ID** : 1645690

COLLECTED BY : REG. NO./LAB NO. : 012410170023

 REFERRED BY
 : 17/Oct/2024 10:26 AM

 BARCODE NO.
 : 01519042
 COLLECTION DATE
 : 17/Oct/2024 10:27 AM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 17/Oct/2024 11:47 AM

**CLIENT ADDRESS**: 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name	Value	Linit	Dialogical Deference interval
rest ivame	Value	Unit	Biological Reference interval
LYMPHOCYTES	31	%	20 - 40
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY			
EOSINOPHILS	4	%	1 - 6
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY			
MONOCYTES	7	%	2 - 12
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY		0/	0.1
BASOPHILS	0	%	0 - 1
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY			
ABSOLUTE LEUKOCYTES (WBC) COUNT			
ABSOLUTE NEUTROPHIL COUNT	3776	/cmm	2000 - 7500
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	,		
ABSOLUTE LYMPHOCYTE COUNT	2018	/cmm	800 - 4900
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	0.40		10 110
ABSOLUTE EOSINOPHIL COUNT	260	/cmm	40 - 440
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY  ABSOLUTE MONOCYTE COUNT	457	lomm	00 000
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	456	/cmm	80 - 880
ABSOLUTE BASOPHIL COUNT	0	/cmm	0 - 110
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	U	/ CITIIII	0-110
PLATELETS AND OTHER PLATELET PREDICTIVE MARKE	ERS.		
		/one me	150000 450000
PLATELET COUNT (PLT) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	202000	/cmm	150000 - 450000
PLATELETCRIT (PCT)	0.28	%	0.10 - 0.36
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	0.20	/0	0.10 - 0.30
MEAN PLATELET VOLUME (MPV)	14 <sup>H</sup>	fL	6.50 - 12.0
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	14.	"-	0.30 12.0
PLATELET LARGE CELL COUNT (P-LCC)	106000 <sup>H</sup>	/cmm	30000 - 90000
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	100000		
PLATELET LARGE CELL RATIO (P-LCR)	52.5 <sup>H</sup>	%	11.0 - 45.0
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	1/0	0/	45.0.47.0
PLATELET DISTRIBUTION WIDTH (PDW)	16.2	%	15.0 - 17.0
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE			
NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD			



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana
KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana
0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

**NAME** : Mr. JARMAN SINGH

**AGE/ GENDER** : 74 YRS/MALE **PATIENT ID** : 1645690

**COLLECTED BY** REG. NO./LAB NO. :012410170023

REFERRED BY **REGISTRATION DATE** : 17/Oct/2024 10:26 AM BARCODE NO. :01519042 **COLLECTION DATE** : 17/Oct/2024 10:27AM CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE : 17/Oct/2024 12:04PM

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit **Biological Reference interval** 

#### **CLINICAL CHEMISTRY/BIOCHEMISTRY GLUCOSE FASTING (F)**

85.77 GLUCOSE FASTING (F): PLASMA mg/dL NORMAL: < 100.0

by GLUCOSE OXIDASE - PEROXIDASE (GOD-POD) PREDIABETIC: 100.0 - 125.0

DIABETIC: > 0R = 126.0

INTERPRETATION
IN ACCORDANCE WITH AMERICAN DIABETES ASSOCIATION GUIDELINES:

1. A fasting plasma glucose level below 100 mg/dl is considered normal.

2. A fasting plasma glucose level between 100 - 125 mg/dl is considered as glucose intolerant or prediabetic. A fasting and post-prandial blood test (after consumption of 75 gms of glucose) is recommended for all such patients.

3. A fasting plasma glucose level of above 125 mg/dl is highly suggestive of diabetic state. A repeat post-prandial is strongly recommended for all such patients. A fasting plasma glucose level in excess of 125 mg/dl on both occasions is confirmatory for diabetic state.



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST





(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mr. JARMAN SINGH

**AGE/ GENDER** : 74 YRS/MALE **PATIENT ID** : 1645690

COLLECTED BY : REG. NO./LAB NO. : 012410170023

 REFERRED BY
 : 17/Oct/2024 10:26 AM

 BARCODE NO.
 : 01519042
 COLLECTION DATE
 : 17/Oct/2024 10:27 AM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 17/Oct/2024 12:04 PM

**CLIENT ADDRESS**: 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name	Value	Unit	Biological Reference interval			
LIPID PROFILE : BASIC						
CHOLESTEROL TOTAL: SERUM by CHOLESTEROL OXIDASE PAP	147.37	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0			
TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)	97.43	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0			
HDL CHOLESTEROL (DIRECT): SERUM by SELECTIVE INHIBITION	47.03	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 - 60.0 HIGH HDL: > OR = 60.0			
LDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	80.85	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0			
NON HDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	100.34	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0			
VLDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	19.49	mg/dL	0.00 - 45.00			
TOTAL LIPIDS: SERUM by CALCULATED, SPECTROPHOTOMETRY	392.17	mg/dL	350.00 - 700.00			
CHOLESTEROL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	3.13	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0			
LDL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	1.72	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0			



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)





(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

**NAME** : Mr. JARMAN SINGH

AGE/ GENDER : 74 YRS/MALE **PATIENT ID** : 1645690

**COLLECTED BY** REG. NO./LAB NO. :012410170023

REFERRED BY **REGISTRATION DATE** : 17/Oct/2024 10:26 AM BARCODE NO. :01519042 **COLLECTION DATE** : 17/Oct/2024 10:27AM CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE : 17/Oct/2024 12:04PM

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit **Biological Reference interval** 

TRIGLYCERIDES/HDL RATIO: SERUM 2.07<sup>L</sup> **RATIO** 3.00 - 5.00by CALCULATED, SPECTROPHOTOMETRY

**INTERPRETATION:** 

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co-primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

End Of Report \*\*\*



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

